Recent Updates
Recently added Catalysts
INSM

Insmed to Host Third Quarter 2022 Financial Results Conference Call on Thursday, October 27, 2022 Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...

Key Takeaway: BRIDGEWATER, N.J. , Oct. 13, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its third quarter 2022 financial results

Full Press Release Details

BRIDGEWATER, N.J. , Oct. 13, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its third quarter 2022 financial results on Thursday, October 27, 2022 .
Insmed management will host a conference call for investors beginning at 8:30 a.m. ET on Thursday, October 27, 2022 to discuss the financial results and provide a business update.
Shareholders and other interested parties may participate in the conference call by dialing (844) 200-6205 (U.S.) or (929) 526-1599 (international) and referencing access code 889963. The call will also be webcast live on the company's website at www.insmed.com .
A replay of the conference call will be accessible approximately 2 hours after its completion through November 26, 2022 , by dialing (866) 813-9403 (U.S.) or (+44) 204-525-0658 (international) and referencing access code 035584. A webcast of the call will also be archived for 90 days under the Investor Relations section of the company's website at www.insmed.com .
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States , Europe , and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey , with a footprint across Europe and in Japan . For more information, visit www.insmed.com .
Eleanor Barisser Associate Director, Investor Relations Insmed (718) 594-5332 [email protected]
Mandy Fahey Executive Director, Corporate Communications Insmed (732) 718-3621 [email protected]
SOURCE Insmed Incorporated

21 %

Last updated: Oct 13, 2022